109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
丁苯酞对阿尔茨海默病进展的影响：一项回顾性队列分析
Authors Zhang Y , Qiu J , Shang Y , Zhao X, Yang S, Chen Y, Dai S , Ai M , Huang W, Zhang J , Liu X
Received 16 June 2025
Accepted for publication 7 October 2025
Published 18 November 2025 Volume 2025:21 Pages 2495—2511
DOI https://doi.org/10.2147/NDT.S547319
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Taro Kishi
Yishu Zhang,1,* Jiating Qiu,1,* Yajun Shang,2,* Xiaoxiao Zhao,3 Shengfu Yang,4 Yili Chen,5 Shujuan Dai,1 Mingda Ai,1 Wei Huang,6 Junyan Zhang,7 Xiaolei Liu1
1Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 3Department of Neurology, Lijiang People’s Hospital, Lijiang, People’s Republic of China; 4Department of Neurology, Tengchong People’s Hospital, Tengchong, People’s Republic of China; 5Department of Neurology, Dali Bai Autonomous Prefecture People’s Hospital, Dali, People’s Republic of China; 6Department of Neurosurgery, The First People’s Hospital of Yunnan Province, Kunming, People’s Republic of China; 7Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaolei Liu, Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People’s Republic of China, Email ring@vip.163.com Junyan Zhang, Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China, Email richard.zhang@both-win.net
Objective: To evaluate the efficacy of DL-3-n-butylphthalide (NBP), a synthetic compound that has shown neuroprotective effects, on cognitive function, psychiatric–behavioral symptoms, and daily activities in patients with Alzheimer’s disease (AD).
Methods: This retrospective cohort study included patients with AD treated with or without NBP. Disease deterioration and decline were defined by changes in Clinical Dementia Rating–Sum of Boxes (CDR-SB) over six months. Multivariate logistic regression, inverse probability of treatment weighting (IPTW) and overlap-weighted propensity score matching (PSM) were used to adjust for confounding.
Results: Totally 100 were included in this study, with 39 classified as the NBP group and 61 as the non-NBP group. NBP was associated with lower odds of deterioration (adjusted odds ratio [OR] = 0.19, 95% confidence interval [CI]: 0.04– 0.88, p = 0.034) and decline (adjusted OR = 0.10, 95% CI: 0.03– 0.49, p = 0.001). In IPTW and PSM analyses, deterioration occurred in 4.31% vs 22.10% and 4.06% vs 24.27%, and decline in 4.31% vs 39.38% and 4.06% vs 44.28% for the NBP and non-NBP groups, respectively.
Conclusion: NBP was associated with reduced risks of clinical worsening and helped preserve cognitive and behavioral functions in patients with AD. These results highlight the potential of NBP as a promising therapeutic option in AD management. Future randomized controlled trials are necessary to validate these findings and assess the long-term efficacy of NBP in clinical settings.
Significance: This real-world study suggests that NBP may slow disease progression and preserve cognitive and behavioral function in AD.
Keywords: Alzheimer’s disease, cognitive impairment, DL-3-n-butylphthalide, CDR-SB
1Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 3Department of Neurology, Lijiang People’s Hospital, Lijiang, People’s Republic of China; 4Department of Neurology, Tengchong People’s Hospital, Tengchong, People’s Republic of China; 5Department of Neurology, Dali Bai Autonomous Prefecture People’s Hospital, Dali, People’s Republic of China; 6Department of Neurosurgery, The First People’s Hospital of Yunnan Province, Kunming, People’s Republic of China; 7Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaolei Liu, Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People’s Republic of China, Email ring@vip.163.com Junyan Zhang, Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China, Email richard.zhang@both-win.net
Objective: To evaluate the efficacy of DL-3-n-butylphthalide (NBP), a synthetic compound that has shown neuroprotective effects, on cognitive function, psychiatric–behavioral symptoms, and daily activities in patients with Alzheimer’s disease (AD).
Methods: This retrospective cohort study included patients with AD treated with or without NBP. Disease deterioration and decline were defined by changes in Clinical Dementia Rating–Sum of Boxes (CDR-SB) over six months. Multivariate logistic regression, inverse probability of treatment weighting (IPTW) and overlap-weighted propensity score matching (PSM) were used to adjust for confounding.
Results: Totally 100 were included in this study, with 39 classified as the NBP group and 61 as the non-NBP group. NBP was associated with lower odds of deterioration (adjusted odds ratio [OR] = 0.19, 95% confidence interval [CI]: 0.04– 0.88, p = 0.034) and decline (adjusted OR = 0.10, 95% CI: 0.03– 0.49, p = 0.001). In IPTW and PSM analyses, deterioration occurred in 4.31% vs 22.10% and 4.06% vs 24.27%, and decline in 4.31% vs 39.38% and 4.06% vs 44.28% for the NBP and non-NBP groups, respectively.
Conclusion: NBP was associated with reduced risks of clinical worsening and helped preserve cognitive and behavioral functions in patients with AD. These results highlight the potential of NBP as a promising therapeutic option in AD management. Future randomized controlled trials are necessary to validate these findings and assess the long-term efficacy of NBP in clinical settings.
Significance: This real-world study suggests that NBP may slow disease progression and preserve cognitive and behavioral function in AD.
Keywords: Alzheimer’s disease, cognitive impairment, DL-3-n-butylphthalide, CDR-SB